4 executives, valuation gain of 6.1 to 12.2 billion won only at the public offering price
It is estimated that 600 employees of employee stocks and an average of 7,400 shares were allocated.
If you record’Dad Sang’, you can expect a profit of 100,000 won per share.. 7.8 billion won
viewer
SK Bioscience’s subscription to public stocks held for two days on the 9th to 10th was attracting a record-breaking margin of 64 trillion won, and as a result of the huge success, interest is also drawing attention from executives and employees who were assigned employee stock ownership. It is calculated that if SK Bioscience’s share price continues to rise after listing, the average profit per employee of employee stockholders can reach KRW 7.8 billion.
According to SK Bioscience’s investment prospects on the 10th, the company paid a total of 546,270 shares of stock options (right to purchase stocks) to four executives, including CEO Ahn Jae-yong. Stock options are the right to buy certain stocks at a set price. The exercise price of the stock options granted to these executives by SK Bioscience is 9,145 won per share, with a total valuation gain of 30.5 billion won compared to the offering price of 65,000 won. Each executive can enjoy a margin of KRW 6.1 billion and a maximum margin of KRW 12.2 billion.
In addition, if SK Bioscience records’Daesang (the initial price is double the public offering price and goes directly to the upper limit price)’ after listing, the price will soar to 169,000 won per share. In this case, the total amount of stock option valuation gains for four executives is expected to reach 87.3 billion won (17.5 billion-34.9 billion won per person).
Employees who received SK Bioscience’s stock ownership are also expected to receive considerable valuation gains. In this subscription, 4.59 million shares were allocated to our stock ownership. Of these, the number of shares subscribed to by members of employee stock ownership is 4.94 million. According to the company, out of 827 employees of the company, about 600 members actually participated in the subscription to employee stock ownership. In other words, if an average of about 7,484 shares per person is received, and the performance is realized, the valuation profit per person is expected to reach an average of 780 million won. However, the newly issued employee stocks cannot be sold for one year after listing.
The share price of SK Chemicals, the major shareholder, is also expected to rise due to the success of SK Bioscience’s public offering. SK Chemicals currently holds 60 million shares of SK Bioscience. After the listing of SK Bioscience, if the stock price is 130,000 won, the equity value will increase to 7.8 trillion won.
SK Chemicals’ market capitalization based on the closing price of the day is 3.25 trillion won, which is less than the standard value of 3,900 trillion won in the public offering of its SK Bioscience stake.
/ Reporter Kim Kyung-mi [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >